Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 687 participants.
Also called NCT04237493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 687 participants
- Sponsor
- University of Jordan
- Registry
-
NCT04237493
-
- Other papers using this trial's data
- Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Jordan
- Registry status
- Completed
Technical summary
Registry record NCT04237493. Randomized; no masking; primary purpose treatment. Start 2017-02-14 (actual); primary completion 2017-07-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin and Glimepiride (Low Dosage)
- Intervention (Drug)
- Metformin and Vildagliptin (Low Dosage)
- Intervention (Drug)
- Metformin and Insulin Glargine U100 (Low Dosage)
- Intervention (Drug)
- Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage)
- Intervention (Drug)
- Metformin and Glimepiride (Regular Dosage)
- Intervention (Drug)
- Metformin and Vildagliptin (Regular Dosage)
- Intervention (Drug)
- Metformin and Insulin Glargine U100 (Regular Dosage)
- Intervention (Drug)
- Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)
- Lead sponsor
- University of Jordan
Record details
- Record id
cardio:ct-nct04237493- Content hash
e866e1bf3e2729bc40b3962e2bcb4149a43885dbdcd88bdb095e550a3a4d40b7